Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.52 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.49 |
| ▸ | FEN1 | P39748 | 2/20 | 0.49 |
| ▸ | MMP13 | P45452 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1769253 | 0.90 | CHEK2 (0.56) | GPR119CHEK2ALOX5APFEN1 | |
| SCHEMBL1769099 | 0.90 | GPR119 (0.57) | GPR119CHEK2 | |
| SCHEMBL19610292 | 0.86 | GPR119 (0.54) | GPR119CHEK2ALOX5APFEN1 | |
| SCHEMBL22756382 | 0.85 | GPR119 (0.56) | GPR119CHEK2ALOX5APFEN1 | |
| SCHEMBL26311640 | 0.85 | GPR119 (0.53) | GPR119CHEK2HDAC1ALOX5APFEN1 | |
| SCHEMBL21398088 | 0.85 | GPR119 (0.53) | GPR119CHEK2HDAC1ALOX5APFEN1 | |
| SCHEMBL14006542 | 0.85 | GPR119 (0.53) | GPR119CHEK2ALOX5APFEN1 | |
| SCHEMBL31071572 | 0.85 | GPR119 (0.53) | GPR119CHEK2 | |
| SCHEMBL13876978 | 0.85 | KDM4E (0.56) | GPR119 | |
| SCHEMBL31330775 | 0.84 | GPR119 (0.54) | GPR119CHEK2HDAC1ALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9000010-B2 | Alkyl-heterocycle carbamate derivatives, their preparation and their therapeutic application | SANOFI (FR) | 2015-04-07 | — | — | US | disclosed |
| EP-2526100-B1 | ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI SA (FR) | 2013-12-04 | — | — | EP | disclosed |
| US-20120295909-A1 | ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI (FR) | 2012-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295909-A1 | ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | PRMT9, PRMT8, CBR1 | GPR119 242/4885CHEK2 3802/4885HDAC1 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.